JAK1/2 inhibitor ruxolitinib restores the responsiveness to hypoxia in pulmonary arterial hypertension-iPSC-derived endothelial cells

29 August 2017 (12:03 - 12:12)
Organised by:
Congress Presentation Part of: Progress in the management of pulmonary hypertension Chronic pulmonary hypertension ESC Premium Access ESC Congress 2017
You may be interested in
thumbnail
Congress Presentation
3 September 2019
thumbnail
Congress Presentation
2 September 2019
thumbnail
Congress Presentation